Karuna Therapeutics, Inc. - Common Stock (NQ:KRTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	326.49 (1)
Ask (Size)	329.94 (1)
Prev. Close	329.83
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	37,443,954
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect ↗

February 27, 2024

Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks.

Via Benzinga

Karuna Therapeutics: Q4 Earnings Insights ↗

February 22, 2024

Via Benzinga

Performance

More News

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

February 22, 2024

From Karuna Therapeutics, Inc.

Via Business Wire

Mental Health Mavericks: 3 Stocks Changing the Game ↗

February 21, 2024

Via InvestorPlace

This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space ↗

February 16, 2024

Via Benzinga

Mizuho Downgrades Karuna Therapeutics: Here's What You Need To Know ↗

January 26, 2024

Via Benzinga

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

February 14, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst ↗

February 06, 2024

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

February 05, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

January 30, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)

January 26, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

ABBV: This Top Biotech Just Went On A Buying Spree ↗

January 25, 2024

Via Talk Markets

January 22, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Bullish Continuation In '24? 3 Market Areas To Watch ↗

January 10, 2024

Via Talk Markets

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

Via Benzinga

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Via Investor's Business Daily

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

January 04, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

December 31, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

December 29, 2023

Via MarketBeat

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review ↗

December 29, 2023

Via Investor's Business Daily

Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday ↗

December 28, 2023

Via Benzinga

December 26, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst ↗

December 26, 2023

Via Benzinga

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100% ↗

December 26, 2023

Via Investor's Business Daily

Why Is RayzeBio (RYZB) Stock Up 100% Today? ↗

December 26, 2023

Via InvestorPlace

Frequently Asked Questions

Is Karuna Therapeutics, Inc. - Common Stock publicly traded?

Yes, Karuna Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Karuna Therapeutics, Inc. - Common Stock trade on?

Karuna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Karuna Therapeutics, Inc. - Common Stock?

The ticker symbol for Karuna Therapeutics, Inc. - Common Stock is KRTX on the Nasdaq Stock Market